Safety of rapid-acting insulin analogs versus regular human insulin.

Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, 38163, USA. akitabch@uthsc.edu

The American journal of the medical sciences 2012 Aug

filter terms:

Insulin is the most effective treatment for both type 1 and type 2 diabetes mellitus. There are several differences in the safety profiles of each type of insulin, including rapid-acting insulin analogs and regular human insulin. The pharmacokinetic and pharmacodynamic properties of those insulin types also differ, as do their safety parameters. Treatment with rapid-acting analogs results in less hypoglycemia overall and decreased frequency of both severe and nocturnal hypoglycemia. In addition, the more rapid onset and shorter duration of action of rapid-acting insulin analogs are associated with greater control of postprandial glucose than regular human insulin. This review will describe the similarities and differences between the safety profiles of rapid-acting insulin analogs.

Citation

Abbas E Kitabchi, Aidar R Gosmanov. Safety of rapid-acting insulin analogs versus regular human insulin. The American journal of the medical sciences. 2012 Aug;344(2):136-41